Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of atabecestat in early Alzheimer's disease
2014-004274-41Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with adverse events or serious adverse events. Started Apr 2015; status: terminated.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-004274-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004274-41.